| Project/Area Number |
17H07058
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Kagawa University (2018)
International University of Health and Welfare (2017) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-08-25 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | Podocyte injury / Diabetic nephropathy / (P)RR antibody / High glucose / Wnt-β-catenin signaling / Wnt-β-catenin |
|---|
| Outline of Final Research Achievements |
In vitro studies were conducted to determine the protective effects of (P)RR monoclonal antibodies (mAb) in podocyte injury. The gene expression data revealed that high glucose intervention reduced the mRNA expression of nephrin compared to the osmotic control group, although the level of gene expression was very small. In contrary, (P)RR mAb treatment caused the increase expression of nephrin mRNA, suggestive of the reduced podocyte injury. In case of podocin and synaptopodin the expression level is unsatisfactory. Therefore, we tried to establish the podocyte injury model in the human immortalized podocyte, AB 8/13 cells. Gene expression of podocin, nephrin and synaptopodin in this human podocyte cell line were also not satisfactory. Therefore, the podocin data are in line with our hypothesis that (P)RR mAb has the potential to protect the podocytes against injurious effects.
|
| Academic Significance and Societal Importance of the Research Achievements |
The podocin gene expression data suggests the protective effects of(P)RR mAb on high glucose-induced podocyte injury, therefore the study will link a translational approach to clinical benefits.
|
